Bruce L.  Claflin net worth and biography

Bruce Claflin Biography and Net Worth

Director of IDEXX Laboratories
Mr. Claflin served as President, Chief Executive Officer and a member of the board of directors of 3Com Corporation from January 2001 until his retirement in 2006, and he served as President and Chief Operating Officer of 3Com from August 1998 to January 2001. Before joining 3Com, Mr. Claflin worked at Digital Equipment Corporation as Senior Vice President, Sales and Marketing from 1997 to 1998 and as Vice President and General Manager of the PC Business Unit from 1995 to 1997. Before joining Digital Equipment Corporation, Mr. Claflin worked at International Business Machines Corporation (IBM) for 22 years, where he held senior management positions in sales, marketing, research and development and manufacturing. Mr. Claflin has served as a member of the board of directors of Ciena Corporation since 2006.  Mr. Claflin was a member of the board of directors of Advanced Micro Devices, Inc. from 2003 until 2017, serving as Chairman of the Board from 2009 to 2016. Mr. Claflin holds an undergraduate degree in Political Science from Pennsylvania State University.

What is Bruce L. Claflin's net worth?

The estimated net worth of Bruce L. Claflin is at least $132,841.92 as of August 14th, 2020. Mr. Claflin owns 304 shares of IDEXX Laboratories stock worth more than $132,842 as of September 28th. This net worth approximation does not reflect any other investments that Mr. Claflin may own. Learn More about Bruce L. Claflin's net worth.

How do I contact Bruce L. Claflin?

The corporate mailing address for Mr. Claflin and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on Bruce L. Claflin's contact information.

Has Bruce L. Claflin been buying or selling shares of IDEXX Laboratories?

Bruce L. Claflin has not been actively trading shares of IDEXX Laboratories during the last quarter. Most recently, Bruce L. Claflin sold 5,629 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $385.11, for a transaction totalling $2,167,784.19. Following the completion of the sale, the director now directly owns 304 shares of the company's stock, valued at $117,073.44. Learn More on Bruce L. Claflin's trading history.

Who are IDEXX Laboratories' active insiders?

IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.

Are insiders buying or selling shares of IDEXX Laboratories?

During the last year, insiders at the sold shares 13 times. They sold a total of 99,063 shares worth more than $47,201,358.58. The most recent insider tranaction occured on August, 31st when CEO Jonathan Jay Mazelsky sold 13,424 shares worth more than $6,873,222.24. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.

Information on this page was last updated on 8/31/2023.

Bruce L. Claflin Insider Trading History at IDEXX Laboratories

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/18/2020Sell5,629$385.11$2,167,784.19304View SEC Filing Icon  
8/14/2020Sell1,111$378.08$420,046.88304View SEC Filing Icon  
8/3/2018Buy415$242.12$100,479.801,415View SEC Filing Icon  
2/7/2018Buy1,000$179.58$179,580.001,000View SEC Filing Icon  
See Full Table

Bruce L. Claflin Buying and Selling Activity at IDEXX Laboratories

This chart shows Bruce L Claflin's buying and selling at IDEXX Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

IDEXX Laboratories Company Overview

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $436.98
Low: $434.98
High: $441.70

50 Day Range

MA: $496.05
Low: $432.42
High: $556.67

2 Week Range

Now: $436.98
Low: $317.06
High: $564.73


396,057 shs

Average Volume

451,062 shs

Market Capitalization

$36.27 billion

P/E Ratio


Dividend Yield